FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to psychiatry, and can be used for correction of drug-induced parkinsonism presented by muscular rigidity, tremor, torsion dystonia and/or acathisia. That is ensured by centrally acting muscle relaxant tizanidine. The preparation is administered 1-3 times in daily dose 2-12 mg.
EFFECT: without reducing dosage of an antipsychotic agent, the invention allows for effective correction of drug-induced parkinsonism manifestations without risk of psychosis exacerbation, development of drug dependence and cognitive toxicity.
1 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF METHYL ETHER OF N-CAPROYL-L-PROLYL-L-TYROSINE (DILEPT) AS AGENT WITH PSYCHOSTIMULANT ACTIVITY | 2015 |
|
RU2593886C1 |
| METHOD FOR TREATING THE CASES OF SCHIZOPHRENIA | 2000 |
|
RU2164799C1 |
| METHOD FOR PREDICTING THE DEGREE OF RISK OF EXTRAPYRAMID SIDE EFFECTS DURING THE BACKGROUND OF HALOPERIDOL THERAPY IN PATIENTS WITH SCHIZOPHRENIC SPECTRUM DISORDERS | 2021 |
|
RU2771180C1 |
| METHOD FOR SUPPORTING MEDICAL DECISIONS ON SELECTION OF ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA IN ORDER TO PREVENT AKATHISIA | 2021 |
|
RU2756614C1 |
| METHOD OF PARKINSON DISEASE TREATMENT | 1994 |
|
RU2057529C1 |
| AGENT FOR PREVENTION AND CORRECTION OF MOTOR, EXTRAPYRAMIDAL DISTURBANCES INDUCED BY NEUROLEPTICS | 2009 |
|
RU2421222C2 |
| METHOD OF SELECTING TREATMENT TACTICS FOR PATIENTS WITH ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL DISORDERS | 2022 |
|
RU2810798C1 |
| METHOD FOR OBJECTIFICATION OF UNDESIRABLE EFFECTS OF PSYCHOPHARMACOLOGICAL DRUGS | 2021 |
|
RU2776835C1 |
| USING HEPTAPEPTIDE FOR TREATING PARKINSON'S DISEASE AND METHOD OF TREATING SUCH DISEASE | 2011 |
|
RU2450822C1 |
| METHOD OF TREATING DISEASES OF SUBCORTICAL NERVOUS SYSTEM | 2000 |
|
RU2168997C1 |
